Dudediligence.

TScan Therapeutics, Inc

TCRXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$1.0MSep ’24$665,000Dec ’24$2.2MMar ’25$3.1MJun ’25$2.5MSep ’25$2.6MDec ’25$982,000Mar ’26$1.1MJun ’26
Net income, by quarter
−$29.9MSep ’24−$35.8MDec ’24−$34.1MMar ’25−$37.0MJun ’25−$35.7MSep ’25−$23.0MDec ’25−$28.7MMar ’26−$30.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$10.1M$13.5M$21.0M$2.8M$10.3M
Operating income−$48.6M−$66.6M−$93.5M−$134.8M−$135.8M
Net income−$48.6M−$66.2M−$89.2M−$127.5M−$129.8M
Operating cash flow−$48.7M−$66.5M−$61.4M−$110.8M−$135.3M
Free cash flow−$58.6M−$70.7M−$64.5M−$114.6M−$139.7M
Cash$161.4M$120.0M$133.4M$178.7M$152.4M
Debtnone on file$29.3M$30.0M$32.1M$32.5M
Shares outstanding11.7M24.0M65.6M112.0M129.8M